Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2017. The document serves as a transaction notification regarding a disposition of securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a regulatory disclosure of a specific share transaction rather than a financial performance report.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Volume: 63,441 shares.
- Transaction Price: Nil consideration (£0.00).
- Market Reference: Closing price on February 10, 2017, was £15.91 per share.
Material Changes
The filing reports a disposal of 63,441 ordinary shares by Sir Andrew Witty, Chief Executive Officer, on February 10, 2017. The shares were transferred as a gift to the University of Nottingham to support student skills and employability. There are no reported changes to the company's financial position or operations in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or contingencies. It is strictly a notification of a PDMR transaction.
Investor Verification Points
- Confirm the charitable nature of the share disposal to the University of Nottingham.
- Verify the transaction date (February 10, 2017) and the associated market price (£15.91) for valuation context.
- Note that this filing does not reflect any change in the company's operational strategy or financial health.